0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IMV
Its shares trade under the ticker IMVIF. It has been listed since 1 June 2018. In the fiscal year to 31 December 2020, it reported revenue of $3,158 and a net loss of $27.4m. At that date it held total assets of $46.0m and shareholders' equity of $30.8m.
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia. The company went IPO on 2018-06-01. The firm is focused on developing a class of cancer vaccines based on DPX, an immune-educating technology platform, which is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its therapeutic candidate, maveropepimut-S (MVP-S) is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S is administered in low doses approximately once every two months, which drives a persistent immune attack on tumor cells. MVP-S is being evaluated in Phase IIB clinical trials for advanced r/r Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer. The firm is also developing a dual-targeted cancer vaccine candidate leveraging the DPX delivery platform, DPX-SurMAGE.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Jun 2018
- Employees
- 63
- Website
- imv-inc.com ↗
Leadership
Pay as last reported
- Mr. Michael BaileyIndependent Chairman of the Board$154,420
- Mr. Andrew HallChief Executive Officer, Director, since 2020$1.0m
- Ms. Brittany DavisonActing Chief Financial Officer, Chief Accounting Officer$388,500
- Dr. Jeremy GraffChief Scientific Officer$589,928
- Dr. Saman MalekiDirector$135,008
- Dr. Michael KalosIndependent Director$108,252
- Ms. Shabnam KazmiIndependent Director
- Mr. Kyle KuvalankaIndependent Director$113,876
- Dr. Markus WarmuthIndependent Director$118,877
- Ms. Joy BessengerSenior Vice President - Investor Relations and Corporate Strategy, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 33
- Social
- 51
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IMV Inc employs 63 full-time staff in Dartmouth, Canada.
- The DPX platform offers novel cancer immunotherapies for solid tumors.
- Maveropepimut-S targets survivin in advanced cancers with low-dose administration.
Weaknesses
- The company has only 63 employees, limiting operational scale.
- Phase IIB trials for DLBCL are still ongoing and unproven.
- Platinum resistant ovarian cancer treatment results remain uncertain currently.
Opportunities
- Expanding DPX technology to infectious diseases like COVID-19 is possible.
- Developing dual-targeted cancer vaccines could broaden the therapeutic pipeline.
- Global demand for novel cancer immunotherapies supports market growth.
Threats
- Competitors in biotechnology may develop superior immune-educating platforms.
- Clinical trial failures for MVP-S could halt progress.
- Regulatory hurdles for new cancer vaccines are significant challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.